Wall Street Zen upgraded shares of Viridian Therapeutics (NASDAQ:VRDN – Free Report) from a strong sell rating to a hold rating in a report released on Saturday morning,Wall Street Zen reports.
A number of other research analysts have also weighed in on the company. Royal Bank Of Canada raised their target price on Viridian Therapeutics from $38.00 to $41.00 and gave the company an “outperform” rating in a report on Thursday, November 5th. Wedbush lifted their target price on Viridian Therapeutics from $41.00 to $42.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. Needham & Company LLC upped their price target on Viridian Therapeutics from $34.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Truist Financial increased their price target on Viridian Therapeutics from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. Finally, HC Wainwright raised their price objective on Viridian Therapeutics from $22.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Viridian Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.00.
View Our Latest Report on Viridian Therapeutics
Viridian Therapeutics Trading Up 6.0%
VRDN opened at $30.19 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 16.95 and a quick ratio of 16.95. Viridian Therapeutics has a fifty-two week low of $13.18 and a fifty-two week high of $34.29. The firm has a market capitalization of $3.42 billion, a PE ratio of -7.86 and a beta of 1.07. The company’s 50-day moving average is $22.12 and its 200 day moving average is $21.80.
Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.21. The business had revenue of $25.75 million for the quarter, compared to analysts’ expectations of $4.72 million. Viridian Therapeutics had a negative net margin of 1,620.79% and a negative return on equity of 77.15%. As a group, research analysts predict that Viridian Therapeutics will post -3.64 earnings per share for the current fiscal year.
Insider Activity at Viridian Therapeutics
In other news, insider Jennifer Tousignant sold 14,212 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total value of $348,194.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 2.40% of the stock is currently owned by corporate insiders.
Institutional Trading of Viridian Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. KBC Group NV purchased a new position in Viridian Therapeutics in the first quarter worth $34,000. Integrated Wealth Concepts LLC bought a new stake in shares of Viridian Therapeutics during the 2nd quarter worth $33,000. State of Wyoming bought a new stake in shares of Viridian Therapeutics during the 2nd quarter worth $43,000. Fulcrum Asset Management LLP purchased a new position in shares of Viridian Therapeutics in the 3rd quarter worth about $97,000. Finally, AlphaCentric Advisors LLC purchased a new position in shares of Viridian Therapeutics in the 3rd quarter worth about $216,000.
Viridian Therapeutics Company Profile
Viridian Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes.
The company’s pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration.
Further Reading
- Five stocks we like better than Viridian Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
